DRKS00028019尚未招募不适用
Clinical and genetic analysis of patients with primary failure of eruption (PFE) and their relatives
CharitéCentrum für Zahn-, Mund- und Kieferheilkunde CC 30 个研究点目标入组 30 人开始时间: 2022年3月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 12 Years 至 one(—)
- 性别
- All
入选标准
- •The patient must be at least 12 years of age, as an asymmetric eruption of the first permanent molars becomes evident (to avoid premature (incorrect) diagnosis of the eruption disorder). Gender does not matter, but must be specified for the evaluation of the genetic analysis.
- •The number of study participants:
- •Spirit. 10 trios with PFE (affected children of two phenotypically healthy or affected parents or affected family members)
排除标准
- •Absence of an impacted tooth in the pretherapeutic orthopantomogram (root growth of the teeth that have not yet erupted is not complete).
- •Abnormal tooth germ position, tooth germ malformation, bone deficit in patients with clefts, dilaceration.
- •Syndromic and systemic diseases
- •Teeth that do not erupt due to lack of space.
研究者
相似试验
招募中
不适用
Genetic and pharmacogenetic analyses of patients with epilepsy and related diseasesG40F45.0Somatization disorderEpilepsyDRKS00025480niversitätsklinikum der RWTH Aachen1,200
已完成
不适用
study on causative factors and laboratory tests on iron deficiency anaemia patients(pandu roga)CTRI/2018/06/014627All India Institute of Ayurveda60
招募中
不适用
A prospective clinical registry study of genetic profiling and targeted therapies in patients with rare cancers; MASTER KEY ProtocolJPRN-UMIN000027552ational Cancer Center1,000
招募中
不适用
A prospective clinical registry study of genetic profiling and targeted therapies in patients with rare hematologic malignancies; MASTER KEY HEM ProtocolRare hematologic malignanciesJPRN-UMIN000036756ational Cancer Center500
已完成
不适用
PHYOS: An observational study of patients with Primary Hyperoxaluria type1autosomal recessive disordersPH1NL-OMON42592Dicerna Pharmaceuticals, Inc7
